Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023)

Monte Rosa Therapeutics (GLUE) has 1 years of Non Operating Investment Income data on record, last reported at -$131000.0 in Q1 2023.

  • For Q1 2023, Non Operating Investment Income changed N/A year-over-year to -$131000.0; the TTM value through Dec 2023 reached -$131000.0, changed N/A, while the annual FY2023 figure was -$131000.0, N/A changed from the prior year.
  • Non Operating Investment Income reached -$131000.0 in Q1 2023 per GLUE's latest filing.
  • Across five years, Non Operating Investment Income topped out at -$131000.0 in Q1 2023 and bottomed at -$131000.0 in Q1 2023.